ClinicalTrials.Veeva

Menu
N

Noble Clinical Research | Tucson, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ESK-001
ACT-541468
Tanezumab
FX006
TAK-279
Vibegron
Lorundrostat
Elagolix
CNTX-4975-05
Daridorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 55 total trials

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femor...

Enrolling
Osteoarthritis (OA) of the Knee
Drug: TPX-100 200mg, Once weekly for 4 weeks
Other: PBS

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (S...

Active, not recruiting
Herpes Zoster (HZ)
Shingles
Biological: Shingrix
Biological: JCXH-105

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Enrolling
Epstein-Barr Virus Infection
Biological: Placebo
Biological: mRNA-1195.1

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Active, not recruiting
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Enrolling
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing...

Active, not recruiting
Early Pregnancy Loss, Delayed Pregnancy Loss
Combination Product: CCT-102 A and CCT-102 B

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerabili...

Active, not recruiting
Obesity
Drug: Petrelintide
Drug: Placebo

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Active, not recruiting
Hypertension
Drug: lorundrostat
Drug: Placebo
Locations recently updated

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling
Generalized Anxiety Disorder (GAD)
Drug: Antidepressant Therapy (ADT)
Drug: ABBV-932

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Moderna logo
Pfizer logo
AbbVie logo
Idorsia Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
A
Apnimed logo
C
C
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems